Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company was founded in 1925 and is based in Bagsvaerd, Denmark.
NVO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Novo Nordisk A S. To summarize, we found that Novo Nordisk A S ranked in the 71th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 273.17%. As for the metrics that stood out in our discounted cash flow analysis of Novo Nordisk A S, consider:
The company has produced more trailing twelve month cash flow than 99.07% of its sector Healthcare.
The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than merely 3.3% of the free cash flow producing stocks we're observing.
NVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 57.3% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Novo Nordisk A S? See ADUS, LCI, CRHM, SGRY, and ARA.
Bagsværd, Denmark, 24 September 2020 – Novo Nordisk today announced the results of the CAPTURE study, a global non-interventional study to uncover the prevalence of cardiovascular disease and risk and its management in people living with type 2 diabetes. The study, the first of its kind and involving nearly 10,000 participants from 13 countries across five continents, showed that 1 in 3 people with type 2 diabetes have established cardiovascular disease, and 9 in 10 of these had atherosclerotic cardiovascular disease. Atherosclerotic cardiovascular disease is caused by the build-up of fats, cholesterol and other substances in and on the artery walls, which narrows the vessels and results in reduced blood flow, potentially leading to events like heart attack and stroke. CAPTURE also high...
To the Editor: Are you diabetic? Or do you happen to have friend or family member who has been diagnosed with diabetes? If so, you know how critical it is to have access to the wonder drug insulin. Because access to insulin can literally mean the difference between life and death, the Illinois State Legislature recently mandated a cap on the cost of insulin at $100 per 30-day supply. The Governor signed it into law and now Illinois residents are protected from price gouging on this critical medication. You would think that every single state legislator would have voted yes on this bill. And you would almost be right. It passed with strong support from both Democrats and Republicans. Our local Republican State Rep. Tom Demmer, voted no and our local Republican State Sen. Brian Stewart di...
Bagsværd, Denmark, 22 September 2020 – Today, Novo Nordisk announced results from three phase 2 clinical trials for insulin icodec, an investigational once-weekly basal insulin analogue, which were presented during the 56th European Association for the Study of Diabetes (EASD) Annual Meeting 2020. The first showed that switching to insulin icodec from other basal insulins using two different switch approaches was efficacious and well-tolerated compared to once-daily insulin glargine U100 and the switching approaches were without an increased risk of clinically significant or severe hypoglycaemic episodes compared to once-daily insulin glargine U100.1 This 16-week phase 2 clinical trial involved 154 adults with type 2 diabetes inadequately controlled with oral antidiabetic drugs and onc...